Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-RCH-10000971

Enrollment

Unknown

Registered

2010-08-09

Start date

2009-02-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain

Interventions

Total:none

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: aged 20-65 years, with +/-20% of ideal body weight, ASA I-II

Exclusion criteria

Exclusion criteria: known history of chronic pain, psychiatric diseases, diabetes mellitus, severe cardiovascular diseases, kidney or liver diseases, alcohol or drug abuse,pregnancy or at lactation period. Patients who had consumed drugs (1week) or foods (3 days) known to inhibit or induce the expression of CYP3A4 enzymes prior to surgery

Design outcomes

Primary

Measure	Time frame
CYP3A4*1G polymorphism;Plasma concentration of fentanyl;Postoperative 24 H visual analogue scale;	—

Countries

China

Contacts

Public ContactZhang Xianwei

znpain@sina.com+86 13037154560

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026